Literature DB >> 7240674

Partial remission of hyperprolactinemic amenorrhea after bromocriptine-induced pregnancy.

C Campagnoli, L Belforte, F Massara, C Peris, G M Molinatti.   

Abstract

Clinical and/or biological improvement has been observed in 7 out of 17 patients with hyperprolactinemic amenorrhea followed for 6-15 months after the successful outcome of bromocriptine (Parlodel, Sandoz)- induced pregnancy. The ovulatory cycle was resumed in 2 out of these 7 patients (with subsequent spontaneous conception in 1); in 3 others the medroxyprogesterone acetate test became positive. In all cases, post-partum prolactin values were considerably reduced. The possible causes of this improvement are discussed, examining the present data and those in the literature. Regressive lesions, due for example to vascularization defects or hemorrhage occurring in the prolactin-secreting tissue, as a result of the hyperplastic stimulus of estrogens during pregnancy, are suggested as a possible explanation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240674     DOI: 10.1007/BF03349421

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells.

Authors:  H M Lloyd; J D Meares; J Jacobi
Journal:  Nature       Date:  1975-06-05       Impact factor: 49.962

2.  Hyperprolactinaemic amenorrhoea--results of treatment with bromocriptine.

Authors:  T Bergh; S J Nillius; L Wide
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1978

3.  Bromocriptine treatment of prolactinomas.

Authors:  T Bergh; S J Nillius; P O Lundberg; L Wide
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

4.  Bromocriptine treatment of prolactinomas.

Authors:  K von Werder; T Eversmann; R Fahlbusch; H K Rjosk
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

5.  Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-amenorrhea syndrome with bromocriptine.

Authors:  S W Lamberts; H J Seldenrath; H G Kwa; J C Birkenhäger
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

6.  Resolution of hyperprolactinaemia after bromocriptine-induced pregnancy.

Authors:  E A Cowden; J A Thomson
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

7.  Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine.

Authors:  S J Nillius; T Bergh; P O Lundberg; J Stahle; L Wide
Journal:  Fertil Steril       Date:  1978-12       Impact factor: 7.329

8.  Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors.

Authors:  R Mornex; J Orgiazzi; B Hugues; J C Gagnaire; B Claustrat
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

9.  Ergot-induced inhibition of pituitary tumor growth in rats.

Authors:  S K Quadri; K H Lu; J Meites
Journal:  Science       Date:  1972-04-28       Impact factor: 47.728

10.  Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumors.

Authors:  T Bergh; S J Nillius; L Wide
Journal:  Br Med J       Date:  1978-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.